The Case for Response Adaptive Trial Design for Rare Diseases
June 27th 2019As pharma businesses shift their focus away from ‘blockbusters’ to treatments for rare diseases, clinical trial design must also go through a period of change and should consider response-adaptive over traditional randomized controlled trial designs.